Nucala vs. Fasenra for Severe Asthma: Which Biologic Is Better?
For patients with severe eosinophilic asthma, biologic medications can dramatically reduce asthma attacks and the need for oral steroids. Two commonly used options are Nucala (mepolizumab) and Fasenra (benralizumab).
Both target eosinophilic inflammation, but they work in slightly different ways.
What Is Eosinophilic Asthma?
Eosinophils are white blood cells that contribute to airway inflammation. Some patients with severe asthma have persistently elevated eosinophils despite using high-dose inhaled corticosteroids and other controller medications.
When eosinophils are an important driver of asthma, medications targeting the interleukin-5, or IL-5, pathway can significantly improve asthma control.
Both Nucala and Fasenra are designed for this type of asthma.
How Does Nucala Work?
Nucala (mepolizumab) is a monoclonal antibody that binds directly to IL-5.
IL-5 is an important signal responsible for the growth, activation, and survival of eosinophils. By blocking IL-5, Nucala reduces the number of eosinophils circulating in the blood and present in the airways.
Nucala is administered by subcutaneous injection on a regular schedule.
How Does Fasenra Work?
Fasenra (benralizumab) takes a different approach.
Instead of binding IL-5 itself, Fasenra binds to the IL-5 receptor on eosinophils. This causes the immune system to rapidly remove eosinophils from the bloodstream.
As a result, Fasenra typically produces nearly complete depletion of circulating eosinophils.
After the initial treatment period, Fasenra is given less frequently than Nucala, which can be an important convenience factor for some patients.
Nucala vs. Fasenra: Which Works Better?
There is no simple answer.
Both medications have been shown to:
- Reduce severe asthma exacerbations
- Improve asthma control
- Reduce emergency visits and hospitalizations
- Improve lung function in many patients
- Reduce dependence on oral corticosteroids
- Lower blood eosinophil levels
Studies comparing the available biologics indirectly have generally found that Nucala and Fasenra have similar overall effectiveness in severe eosinophilic asthma.
There have not been enough large randomized head-to-head trials to conclude that one medication is clearly superior for every patient.
One Major Difference: What Happens to Eosinophils?
This is one of the most interesting differences between the two medications.
Nucala lowers eosinophils substantially but generally leaves a small population of circulating eosinophils.
Fasenra produces much more profound eosinophil depletion because it targets the eosinophil directly through its IL-5 receptor.
Whether completely eliminating circulating eosinophils provides a meaningful clinical advantage for every patient remains uncertain.
In practice, some patients respond extremely well to Nucala, while others respond better to Fasenra.
What About Oral Steroid-Dependent Asthma?
Both medications can be useful when severe asthma requires repeated or chronic oral corticosteroid treatment.
Clinical trials have demonstrated that both Nucala and Fasenra can allow many patients to reduce their oral corticosteroid exposure while maintaining asthma control.
Reducing chronic prednisone use is particularly important because long-term systemic corticosteroids can contribute to osteoporosis, diabetes, cataracts, weight gain, infections, hypertension, and other complications.
Does the Eosinophil Count Matter?
Yes.
Patients with evidence of eosinophilic inflammation are generally more likely to respond to medications targeting the IL-5 pathway.
However, choosing a biologic should involve more than looking at a single eosinophil result.
An allergist or asthma specialist may also consider:
- Previous eosinophil counts
- Number of asthma attacks in the past year
- Previous hospitalizations
- Oral steroid requirements
- Lung function
- Nasal polyps or chronic sinus disease
- Other allergic conditions
- Previous biologic treatments
- Insurance coverage
- Injection frequency and patient preference
Importantly, eosinophil counts can be suppressed by oral corticosteroids, so a low result obtained while taking prednisone does not necessarily exclude eosinophilic asthma.
Is Fasenra Better Because It Eliminates More Eosinophils?
Not necessarily.
Fasenra’s ability to rapidly deplete eosinophils is biologically impressive, but a larger reduction in a laboratory value does not automatically translate into better asthma control for every patient.
Clinical outcomes matter more than the eosinophil number alone.
The goal of treatment is to reduce asthma attacks, improve breathing and quality of life, minimize oral steroid exposure, and ideally achieve sustained asthma control or remission.
Which One Is More Convenient?
Fasenra has an advantage in dosing frequency for many patients because, after its initial doses, injections are spaced farther apart.
Nucala is administered more regularly.
For a patient who responds equally well to either medication, injection frequency can therefore influence the decision.
However, convenience should not outweigh selecting the biologic that best matches the patient’s asthma phenotype and associated conditions.
What If One Biologic Doesn’t Work?
Failure of one biologic does not mean that all biologic therapy will fail.
Patients may respond differently even to medications targeting closely related pathways.
If asthma remains poorly controlled after an adequate trial, the diagnosis, adherence, inhaler technique, comorbid conditions, and inflammatory phenotype should be reassessed.
A specialist may then consider switching to another biologic, including another IL-5 pathway medication or a biologic targeting a different inflammatory pathway.
Nucala vs. Fasenra: The Bottom Line
For severe eosinophilic asthma, both Nucala and Fasenra are highly effective treatment options.
Nucala blocks IL-5 and substantially reduces eosinophilic inflammation.
Fasenra targets the IL-5 receptor and produces much more complete eosinophil depletion, while also offering less frequent maintenance injections.
Neither medication is automatically the best choice for every patient.
The ideal biologic depends on the patient’s eosinophil history, asthma exacerbations, oral steroid use, associated allergic conditions, previous treatment response, and individual preferences.
A board-certified allergist can evaluate these factors and determine which biologic is most appropriate for a particular patient’s severe asthma.
New Asthma Drug Nucala (Mepolizumab) for Severe Eosinophilic Asthma